| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1104547651 |
| P356 | DOI | 10.1186/S13058-018-0989-8 |
| P932 | PMC publication ID | 6000975 |
| P698 | PubMed publication ID | 29898752 |
| P50 | author | Edith A. Perez | Q18389345 |
| P2093 | author name string | Nicholas Fox | |
| Nadine Norton | |||
| Karla Ballman | |||
| Keith L Knutson | |||
| Winston W Tan | |||
| Raphael Clynes | |||
| Christie-Ann McCarl | |||
| Donald Northfelt | |||
| Courtney L Erskine | |||
| Gerardo Colon-Otero | |||
| Mark Pegram | |||
| Brian M Necela | |||
| Carmen Calfa | |||
| Kathleen S Tenner | |||
| P2860 | cites work | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | Q38743961 |
| Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer | Q38960107 | ||
| Normal values for free light chains in serum different age groups | Q39615753 | ||
| Bound and Free Light Chains in Serum from Patients Affected with Various Neurological Diseases | Q39645349 | ||
| Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring. | Q40155719 | ||
| Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes | Q40568569 | ||
| Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain | Q40745788 | ||
| Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials | Q47869726 | ||
| Advances in the management of HER2-positive early breast cancer | Q50084900 | ||
| First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. | Q51170722 | ||
| Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice | Q73074966 | ||
| Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer | Q79979044 | ||
| Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy | Q81038993 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer | Q27853134 | ||
| Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention | Q28067145 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) | Q28291395 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | Q33964848 | ||
| Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. | Q34484185 | ||
| The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 | ||
| Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria | Q35677457 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer | Q36463604 | ||
| P433 | issue | 1 | |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 52 | |
| P577 | publication date | 2018-06-14 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. | |
| P478 | volume | 20 |
| Q90221008 | Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis | cites work | P2860 |
Search more.